
Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Support Scalable Adenovirus Vaccine Production
Thermo Fisher Scientific, a global leader in serving science, has announced the launch of Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined and animal origin-free cell culture medium developed to support suspension HEK293 cell growth and high-titer adenovirus production. The new product is designed to help vaccine developers improve upstream manufacturing processes and advance adenovirus-based vaccine production from early-stage process development to larger-scale manufacturing operations.
The newly introduced medium is available in both liquid and Gibco Advanced Granulation Technology (AGT™) formats, providing manufacturers with flexible options to support different production requirements. By combining robust cell growth capabilities with adenovirus productivity and simplified processing, VaxEvo CD 293 Medium aims to address the evolving needs of vaccine developers working with suspension-based HEK293 cell culture systems.
The launch reflects the growing demand for scalable and efficient manufacturing technologies as vaccine developers continue to expand the use of adenoviral vectors and adenovirus-based vaccines. These technologies require reliable upstream production processes capable of delivering consistent performance, supporting high viral yields and accommodating increasing manufacturing volumes.
As the biopharmaceutical industry advances toward more scalable viral vector and vaccine manufacturing platforms, selecting the appropriate cell culture medium has become an important consideration. Media formulations can influence cell growth, viral productivity, process consistency and the overall complexity of manufacturing operations. Thermo Fisher Scientific developed VaxEvo CD 293 Medium to provide a purpose-built solution that addresses these requirements while supporting the transition from laboratory-scale development to commercial manufacturing.
Supporting Suspension HEK293 Cell Growth and Adenovirus Productivity
HEK293 cells are widely used in biotechnology and biopharmaceutical manufacturing because of their ability to support the production of various viral vectors and biological products. Suspension-adapted HEK293 cells are particularly valuable for manufacturing applications because they can be cultivated in bioreactor systems, enabling production processes to be scaled up more efficiently than traditional adherent cell culture approaches.
In adenovirus manufacturing, maintaining healthy cell growth and achieving high viral productivity are essential for developing efficient production processes. However, manufacturers must also consider media composition, feeding requirements, process compatibility and scalability when establishing upstream workflows.
VaxEvo CD 293 Medium has been developed specifically to support suspension HEK293 cell culture for adenoviral vector and adenovirus vaccine production. Its chemically defined formulation provides a controlled cell culture environment without animal-derived components, helping developers establish manufacturing processes with greater consistency and reduced dependence on animal-origin materials.
The animal origin-free formulation is particularly relevant for vaccine developers seeking to strengthen process control and support manufacturing requirements. Chemically defined media can help reduce variability associated with complex biological ingredients and provide manufacturers with greater control over the composition of their cell culture systems.
The medium is also designed to support high-titer adenovirus production while maintaining robust cell growth. This combination is important because successful viral manufacturing depends not only on achieving sufficient cell density but also on maintaining cellular conditions that support efficient virus production.
Benchmarking Demonstrates Competitive Adenovirus Titers
Thermo Fisher Scientific highlighted the performance of VaxEvo CD 293 Medium through laboratory benchmarking studies conducted using HEK293 cells. According to the company, the medium supported average adenovirus type 5 (Ad5) titers comparable to those achieved with selected supplier media.
In certain comparisons, VaxEvo CD 293 Medium delivered adenovirus titers that were up to 5.7-fold higher than those observed with selected benchmark media. These findings demonstrate the medium’s potential to support improved adenovirus productivity under the laboratory conditions evaluated.
The benchmarking results are particularly relevant for vaccine manufacturers seeking to improve viral yields without introducing unnecessary complexity into their upstream manufacturing processes.
Another important aspect of the product’s performance is its ability to support adenovirus productivity without requiring a dedicated feed in the evaluated comparisons. Thermo Fisher Scientific reported that VaxEvo CD 293 Medium demonstrated comparable or higher titers without a dedicated feed when compared with selected benchmark media used alongside their recommended feeding strategies.
Eliminating the need for an additional feeding component in certain workflows may help simplify upstream processing. Feeding strategies can introduce additional operational considerations, including preparation requirements, process timing, material handling and optimization activities.
By potentially reducing these requirements, VaxEvo CD 293 Medium may help developers streamline process development and simplify manufacturing workflows. However, actual performance will depend on the specific cell line, virus system, process conditions and manufacturing parameters used by individual developers.
The company noted that the reported performance results are based on laboratory benchmarking studies and are intended to demonstrate the product’s capabilities in the evaluated experimental settings.
Designed to Reduce Manufacturing Process Complexity
For vaccine manufacturers, process development decisions can have long-term implications for production efficiency and manufacturing readiness. A formulation that performs effectively during early development can help establish a stronger foundation for subsequent process optimization and scale-up activities.
However, transitioning from laboratory-scale experiments to larger manufacturing operations requires careful evaluation of multiple factors. These include cell growth characteristics, viral productivity, media preparation, feeding requirements, process consistency and compatibility with manufacturing equipment.
Thermo Fisher Scientific designed VaxEvo CD 293 Medium to help address these considerations by combining cell growth support and adenovirus productivity within a chemically defined formulation.
The availability of the product in liquid and AGT formats also provides flexibility for different manufacturing environments. Liquid media can support workflows that require ready-to-use formulations, while AGT formats offer an alternative for manufacturers managing media preparation and handling requirements at different production scales.
The AGT technology is intended to provide additional flexibility in media preparation and manufacturing operations. Offering multiple package sizes can also help accommodate the varying material requirements associated with research, process development and larger-scale production activities.
For organizations developing adenovirus-based vaccines, these product characteristics may help reduce the number of process variables that need to be evaluated during development. A simplified upstream process can support more efficient development activities and help manufacturers establish a clearer pathway toward production scale-up.
Supporting the Development of Adenovirus-Based Vaccines
Adenoviruses have an established role in vaccine development and viral vector technologies. Their ability to deliver genetic material into target cells has made them useful platforms for developing vaccines and other therapeutic applications.
Adenovirus-based technologies have been investigated and used across multiple areas of human and animal health. As research and development activities continue, manufacturers require reliable production systems that can support the generation of viral materials at the quantities and quality levels required for different applications.
The growing interest in viral vector-based approaches has also increased the importance of manufacturing technologies that can accommodate both development-stage and larger-scale production requirements.
VaxEvo CD 293 Medium is designed to support vaccine process development scientists and upstream manufacturing teams at human and animal health vaccine manufacturers. Its primary intended applications include adenovirus-based vaccine production and adenoviral vector manufacturing using suspension HEK293 cells.
The formulation is also positioned for applications involving oncolytic virus production, expanding its potential relevance to developers working across different viral manufacturing areas.
By offering a chemically defined and animal origin-free formulation, Thermo Fisher Scientific aims to provide a cell culture solution that can support developers seeking improved process control, manufacturing flexibility and consistent upstream performance.
Thermo Fisher Emphasizes Manufacturing Readiness
Commenting on the launch, Alex Cherkassky, vice president and general manager of Thermo Fisher Scientific’s cell culture business, emphasized the importance of making manufacturing-focused decisions during the early stages of process development.
“Manufacturing readiness begins well before a process reaches the plant. The choices vaccine developers make during process development can shape how they evaluate performance, complexity and the path to scale,” Cherkassky said.
He added that the company developed Gibco VaxEvo CD 293 Medium as a purpose-built starting point to help customers advance suspension-based adenovirus HEK293 processes with greater confidence.
The statement highlights the company’s focus on supporting vaccine manufacturers beyond the initial research and development stage. Selecting an appropriate medium early in process development can influence subsequent optimization activities and the transition toward larger production systems.
For manufacturers, establishing a suitable upstream process from the beginning may help reduce the need for extensive reformulation or process adjustments as production requirements increase.
Thermo Fisher Scientific’s latest launch is intended to address these considerations by providing a medium specifically designed for suspension HEK293 cell growth and adenovirus production.
Product Availability and Commercial Formats
Gibco VaxEvo CD 293 Medium will be available in liquid and multiple AGT package sizes. The different formats are intended to provide flexibility for vaccine developers and manufacturing teams working across various stages of process development and production.
The product’s availability in multiple configurations may help organizations select packaging formats according to their operational requirements, media consumption and manufacturing scale.
Through its Gibco portfolio, Thermo Fisher Scientific provides cell culture products and technologies supporting biopharmaceutical research, process development and manufacturing. The introduction of VaxEvo CD 293 Medium further expands the company’s offerings for developers working with adenovirus-based vaccine and viral vector production platforms.
The company is positioning the new medium as a solution that brings together three important capabilities: support for suspension HEK293 cell growth, competitive adenovirus productivity and simplified upstream processing.
For additional product information, formulation details and availability, customers can visit the official product webpage: thermofisher.com/VaxEvo-CD293-Media.
Advancing Scalable Vaccine Manufacturing
The launch of Gibco VaxEvo CD 293 Medium represents another development in Thermo Fisher Scientific’s efforts to support the evolving requirements of biopharmaceutical and vaccine manufacturing.
As developers continue to pursue scalable adenovirus production platforms, the availability of specialized cell culture media will remain an important factor in improving upstream process performance. Solutions that support robust cell growth, high viral titers and simplified processing can help manufacturers address development challenges while preparing their processes for larger-scale operations.
With its chemically defined, animal origin-free formulation, flexible liquid and AGT formats, and laboratory benchmarking results demonstrating competitive Ad5 productivity, VaxEvo CD 293 Medium is designed to provide vaccine developers with an additional option for suspension HEK293-based manufacturing.
By supporting process development through scale-up, Thermo Fisher Scientific aims to help human and animal health vaccine manufacturers advance adenovirus production workflows and strengthen their manufacturing readiness.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD.



